Padcev (Enfortumab Vedotin)

Enfortumab vedotin is a medicine used to treat bladder cancer and other cancers of the urinary tract. It is given as an infusion into a vein at a clinic, often together with pembrolizumab (Keytruda). It works by finding a protein on cancer cells and delivering a drug that kills them.

Brand names:Padcev
Medication

What people taking Padcev (Enfortumab Vedotin) report

Every report comes from a Lived member, sent anonymously.

Have you tried Padcev (Enfortumab Vedotin) for Bladder Cancer?

NameHow it went

About Padcev (Enfortumab Vedotin)

What It's For

Enfortumab vedotin, sold as Padcev, is a targeted cancer medicine for adults with urothelial cancer. That is the cancer that starts in the lining of the urinary tract: most often the bladder, but also the ureters (the tubes from the kidneys), the inner part of the kidney called the renal pelvis, and the urethra. It is most often given together with pembrolizumab (Keytruda or Keytruda Qlex), an immunotherapy medicine that helps the immune system recognize cancer cells. The pair is used in two situations. When bladder cancer has grown into the bladder's muscle wall but not spread elsewhere (muscle-invasive bladder cancer), the combination is given before surgery to remove the bladder and then continued afterward. When urothelial cancer has spread or cannot be removed with surgery (locally advanced or metastatic), the combination can be the first treatment. In a large trial in that setting, people who received it lived about twice as long on average as those who received standard platinum chemotherapy, roughly 34 months compared with 16. Padcev can also be used on its own for advanced urothelial cancer in adults who have already had immunotherapy and platinum chemotherapy, or who cannot have the chemotherapy drug cisplatin and have had at least one earlier treatment.

How It Works

Padcev is an antibody-drug conjugate: an antibody with a powerful cell-killing drug attached. The antibody part seeks out Nectin-4, a protein that sits on the surface of cells, including urothelial cancer cells. Once it latches on, the cancer cell pulls the whole package inside, where the attached drug, called MMAE (monomethyl auristatin E), is released. MMAE breaks down the internal scaffolding a cell needs to divide, so the cell stops growing and dies. This design aims chemotherapy-like damage at cells carrying the target, though healthy tissues are not fully spared, which is why side effects such as rash and nerve damage are common. Pembrolizumab works differently: it blocks PD-1 (programmed death receptor-1), a brake on immune cells that cancers exploit to avoid attack. In laboratory studies, combining the two increased immune activity and tumor-killing effect.

Dosage & Administration

Padcev is given only at an infusion center or clinic, as a 30-minute drip into a vein. Treatment runs in repeating cycles. With pembrolizumab, Padcev is given on days 1 and 8 of each three-week cycle, and pembrolizumab is usually given after it on the first day. On its own, Padcev is given on days 1, 8 and 15 of a four-week cycle, followed by a week off. The dose is based on body weight, with a set maximum. For muscle-invasive bladder cancer, the number of cycles before and after surgery is planned in advance. For advanced cancer, treatment usually continues as long as it is working and side effects remain manageable. Blood tests, including blood sugar checks, are done regularly, and the dose may be lowered or paused to manage side effects.

Side Effects

Rash and itching are among the most common effects, along with tiredness, hair thinning or loss, changes in taste, diarrhea, nausea, lower appetite and weight loss. Dry, gritty eyes and blurred vision are also common; the care team may suggest artificial tears to prevent dryness and an eye exam if symptoms persist. Padcev carries the US Food and Drug Administration's (FDA's) strongest warning, a boxed warning, for serious skin reactions, including rare and sometimes fatal conditions in which the skin blisters and peels (Stevens-Johnson syndrome and toxic epidermal necrolysis). These are most likely during the first cycle but can happen later, and they are more common when Padcev is combined with pembrolizumab. Contact the care team right away for rings or target-shaped spots on the skin, a rash or itch that keeps getting worse, blistering or peeling, painful sores in the mouth, nose, throat or genital area, or fever and flu-like symptoms with a rash. Nerve damage in the hands and feet (peripheral neuropathy) is common, especially with the combination. It tends to build over months and often does not fully go away after treatment, so early numbness, tingling or weakness is worth reporting so the dose can be adjusted. Padcev can also raise blood sugar sharply, sometimes to diabetic ketoacidosis, a dangerous buildup of acids in the blood, even in people without diabetes. Call the care team right away for strong thirst, frequent urination, confusion or unusual drowsiness, fruity-smelling breath, or nausea, vomiting or stomach pain. Lung inflammation (pneumonitis) is less common but can be serious, so a new or worsening cough or shortness of breath should also be reported right away. If the drug leaks out of the vein during the infusion, it can damage nearby skin, sometimes appearing a day or more later. Redness, swelling, blistering or pain at the infusion site should be reported promptly.

Interactions & Warnings

Padcev can seriously harm a developing baby. A pregnancy test is done before starting in anyone who could become pregnant. Effective birth control is needed during treatment and for 2 months after the last dose for women, and for 4 months after the last dose for men whose partners could become pregnant. Breastfeeding is not recommended during treatment or for 3 weeks afterward. Padcev may also reduce fertility, which is worth discussing before treatment begins if future children matter. People with diabetes or high blood sugar need closer glucose monitoring, and existing numbness or tingling should be mentioned before starting, since Padcev can make it worse. It is generally avoided in people with moderate or severe liver impairment, because the liver clears the attached drug. Some medicines that strongly block the body's drug-processing enzymes, such as the antifungal drug ketoconazole, can raise the level of the cell-killing component and make side effects worse. Tell the cancer team about every prescription, over-the-counter medicine and supplement, including anything prescribed by another doctor during treatment.

What to Expect

Infusion days are relatively short, but treatment means frequent visits: two or three a month, with blood tests and check-ins about skin, nerves, eyes and blood sugar. Skin problems tend to appear early, often in the first weeks, while nerve symptoms usually develop gradually over several months. Many side effects can be managed with creams, antihistamines, eye drops or a dose reduction or pause, and catching them early makes that easier. Scans every few months show whether the cancer is responding. For advanced cancer, Padcev is not usually expected to cure the disease, but in many people it shrinks tumors or holds them in check for a long time. Treatment continues as long as that is the case and side effects stay manageable. For muscle-invasive bladder cancer, the aim is cure: in trials, adding Padcev and pembrolizumab around bladder removal surgery lowered the chance of the cancer returning and improved survival, compared with chemotherapy before surgery or surgery alone. Some people end treatment with lasting numbness in the hands or feet, which is worth weighing and discussing as treatment goes on.

Questions to Ask Your Doctor

  1. 1.Why is Padcev, alone or with pembrolizumab, the right choice for my cancer compared with chemotherapy or other options?
  2. 2.What is the goal of treatment for me, and how and when will we know whether it is working?
  3. 3.Given my blood sugar, nerve or liver history, what extra monitoring will I need?
  4. 4.Which skin, breathing or blood sugar symptoms should I call about right away, and how do I reach the team after hours?
  5. 5.If numbness or tingling starts, at what point would we lower the dose or pause treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.